The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Open accessAbstract
Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of irinotecan. After irinotecan was introduced for the treatment of metastatic colorectal cancer (CRC) at the end of the last century, survival has improved dramatically. Irinotecan is now combined with 5-fluorouracil, oxaliplatin and several molecularly-targeted anticancer drugs, resulting in the extension of overall survival to longer than 30 mo. Severe, occasionally life-threatening toxicity occurs sporadically, even in patients in relatively good condition who have a low risk of chemotherapy-induced toxicity, often causing the failure of irinotecan-based chemotherapy. Clinical pharmacological studies have revealed that such severe toxicity is related to exposure to SN-38 and genetic polymorphisms in UDP-glucuronosyltransferase 1A1 gene. The large inter- and intra-patient variability in systemic exposure to SN-38 is determined not only by genetic factors but also by physiological and environmental factors. This review first summarizes the roles of irinotecan in chemotherapy for metastatic CRC and then discusses the optimal dosing of irinotecan based on the aforementioned factors affecting systemic exposure to SN-38, with the ultimate goal of achieving personalized irinotecan-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Health and economic burden of the projected obesity trends in the USA and the UK
Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L., & Brown, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60814-3 · Cited by 2,692
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Beutler, E., Gelbart, T., & Demina, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8170 · Cited by 853
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9436 · Cited by 485
UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Sotaniemi, E. A., Arranto, A. J., Pelkonen, O., & Pasanen, M. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90166-1 · Cited by 415
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Hosokawa, M. (2008) · Molecules · doi:10.3390/molecules13020412 · Cited by 382
Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse, R. A., Lohrbach, K., Li, L., BOSRON, W. F., & Dolan, M. E. (2000) · PubMed · Cited by 353
Gagné, J.-F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., & Guillemette, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.608 · Cited by 346
Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L. M., Pessa, S., Errante, D., De Pangher, V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5400 · Cited by 338
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326
Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., & Tamai, I. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001909 · Cited by 316
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302
Han, J.-Y., Lim, H.-S., Shin, E. S., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Jang, I.-J., Ho Lee, D., & Soo Lee, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0239 · Cited by 298
Fuchs, C. S., Moore, M. R., Harker, G., Villa, L., Rinaldi, D., & Hecht, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.058 · Cited by 296
Maindrault-Goebel, F., Louvet, C., André, T., Carola, E., Lotz, J. P., Molitor, J. L., Garcia, M. L., Gilles-Amar, V, Izrael, V, Krulik, M., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00149-5 · Cited by 290
Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J.-I., Hamaguchi, T., Yamamoto, N., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328014341f · Cited by 289
Pharmacokinetic and Pharmacodynamic Changes in the Elderly: Clinical Implications
H??mmerlein, A., Derendorf, H., & Lowenthal, D. T. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835010-00004 · Cited by 273
Functional Gene Variants of CYP3A4
Werk, A. N., & Cascorbi, I. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.129 · Cited by 273
André, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J. P., Gilles-Amar, V, Krulik, M., Carola, E., Izrael, V, et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00150-1 · Cited by 267
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262
Lichtman, S. M., Wildiers, H., Chatelut, E., Steer, C., Budman, D., Morrison, V. A., Tranchand, B., Shapira, I., & Aapro, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6583 · Cited by 222
Court, M. H. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903209288 · Cited by 222
Cecchin, E., Innocenti, F., D'Andrea, M., Corona, G., De Mattia, E., Biason, P., Buonadonna, A., & Toffoli, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0314 · Cited by 215
Cyclosporine markedly raises the plasma concentrations of repaglinide
KAJOSAARI, L., NIEMI, M., NEUVONEN, M., LAITILA, J., NEUVONEN, P., & BACKMAN, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.005 · Cited by 207
Hepatic Drug Metabolism and Aging
Durnas, C., Loi, C.-M., & Cusack, B. J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199019050-00002 · Cited by 202
Rothenberg, M. L., Cox, J. V., DeVore, R. F., Hainsworth, J. D., Pazdur, R., Rivkin, S. E., Macdonald, J. S., Geyer, C. E., Sandbach, J., Wolf, D. L., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9 · Cited by 201
Han, J., Lim, H., Yoo, Y., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J., Lee, D. H., Kim, H. T., & Lee, J. S. (2007) · Cancer · doi:10.1002/cncr.22760 · Cited by 195
Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5850 · Cited by 189
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Mechanisms of resistance to topoisomerase I-targeting drugs
Rasheed, Z. A., & Rubin, E. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206935 · Cited by 180
Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
de Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H., Verweij, J., Marsh, S., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100019 · Cited by 171
Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., & Fukuoka, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1068 · Cited by 169
Toffoli, G., Cecchin, E., Gasparini, G., D'Andrea, M., Azzarello, G., Basso, U., Mini, E., Pessa, S., De Mattia, E., Lo Re, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6125 · Cited by 169
International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms
Giacomini, K. M., Balimane, P. V., Cho, S. K., Eadon, M., Edeki, T., Hillgren, K. M., Huang, S.-M., Sugiyama, Y., Weitz, D., Wen, Y., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.12 · Cited by 165
Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications
Guillemette, C., Lévesque, É., & Rouleau, M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.126 · Cited by 163
Innocenti, F., Schilsky, R. L., Ramírez, J., Janisch, L. A., Undevia, S. D., House, L. K., Das, S., Wu, K., Turcich, M., Marsh, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2307 · Cited by 152
Mathijssen, R. H. J., de Jong, F. A., Loos, W. J., van der Bol, J. M., Verweij, J., & Sparreboom, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-913 · Cited by 146
Taxol metabolism and disposition in cancer patients.
Walle, T., Walle, U. K., Kumar, G. N., et al. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06589-4 · Cited by 137
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development
Gerrits, C. J., de Jonge, M., Schellens, J. H. M., Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.491 · Cited by 133
Maindrault‐Gœbel, F., de Gramont, A., Louvet, C., André, T., Carola, É., Gilles-Amar, V., Lotz, J., Tournigand, C., Mabro, M., Molitor, J., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026520812351 · Cited by 131
Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Chu, X., Kato, Y., & Sugiyama, Y. (1997) · PubMed · Cited by 129
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128
Raymond, É., Boige, V., Faivre, S. J., Sanderink, G., Rixe, O., Vernillet, L., Jacques, C. J., Gatineau, M., Ducreux, M. P., & Armand, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.123 · Cited by 119
Pharmacokinetics of repaglinide in subjects with renal impairment
Marbury, T. C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.103973 · Cited by 118
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Sparreboom, A., de Jonge, M. J., de Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H. J., Stoter, G., & Verweij, J. (1998) · PubMed · Cited by 115
Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
Mathijssen, R. H. J., Verweij, J., de Jonge, M. J. A., Nooter, K., Stoter, G., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.81 · Cited by 113
Marcuello, E., Páez, D., Paré, L., Salazar, J., Sebio, A., del Río, E., & Baiget, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.206 · Cited by 112
Han, J., Lim, H., Park, Y. H., Lee, S., & Lee, J. S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.003 · Cited by 107
Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in Man
Bach, B., Hansen, J. M., Kampmann, J. P., Rasmussen, S. N., & Skovsted, L. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106050-00005 · Cited by 105
Stewart, C. F., Panetta, J. C., O'Shaughnessy, M. A., Throm, S. L., Fraga, C. H., Owens, T. S., Liu, T., Billups, C. A., Galindo, C. R., Gajjar, A. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2301 · Cited by 102
Chemotherapy dosing in overweight and obese patients with cancer
Lyman, G. H., & Sparreboom, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.108 · Cited by 98
Zhao, P., Vieira, M. D. L. T., Grillo, J. A., Song, P., Wu, T., Zheng, J., Arya, V., Berglund, E. G., Atkinson, A. J., Sugiyama, Y., et al. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011415528 · Cited by 98
Akaba, K., Kimura, T., Sasaki, A., Tanabe, S., Wakabayashi, T., Hiroi, M., Yasumura, S., Maki, K., Aikawa, S., & Hayasaka, K. (1999) · Journal of Human Genetics · doi:10.1007/s100380050100 · Cited by 96
Xiang, X., Jada, S. R., Li, H. H., Fan, L., Tham, L. S., Wong, C. I., Lee, S. C., Lim, R. S. C., Zhou, Q. Y., Goh, B. C., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230420.05221.71 · Cited by 93
Han, J., Lim, H., Shin, E., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Kim, H. T., & Lee, J. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.019 · Cited by 92
Chu, X., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., et al. (1998) · PubMed · Cited by 90
Klein, C. E. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129502 · Cited by 85
Kalliokoski, A., Backman, J. T., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.74 · Cited by 84
Venook, A. P., Klein, C. E., Fleming, G. F., Hollis, D. R., Leichman, C. G., Hohl, R. J., Byrd, J. C., Budman, D. R., Villalona, M. A., Marshall, J. L., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg493 · Cited by 81
Teft, W. A., Welch, S. A., Lenehan, J. G., Parfitt, J. R., Choi, Y.-H., Winquist, E., & Kim, R. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.5 · Cited by 77
Yamaguchi, H., Kobayashi, M., Okada, M., Takeuchi, T., Unno, M., Abe, T., Goto, J., Hishinuma, T., & Mano, N. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.040 · Cited by 76
Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Fujita, K.-I., & Sparreboom, A. (2010) · Current Clinical Pharmacology · doi:10.2174/157488410791498806 · Cited by 73
Self-citationKehrer, D. F. S., Yamamoto, W., Verweij, J., de Jonge, M. J., de Bruijn, P., & Sparreboom, A. (2000) · PubMed · Cited by 60
Mattia, E. D., Toffoli, G., Polesel, J., D'Andrea, M. R., Corona, G., Zagonel, V., Buonadonna, A., Dreussi, E., & Cecchin, E. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328364b6cf · Cited by 57
Flat-Fixed Dosing of Irinotecan
de Jong, F. A., Mathijssen, R. H. J., Xie, R., Verweij, J., & Sparreboom, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0591 · Cited by 52
Takane, H., Kawamoto, K., Sasaki, T., Moriki, K., Moriki, K., Kitano, H., Higuchi, S., Otsubo, K., & Ieiri, I. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0864-x · Cited by 51
Pharmacology of antineoplastic agents in older cancer patients
Lichtman, S. M., Skirvin, J. A., & Vemulapalli, S. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00120-8 · Cited by 51
Tyrosyl-DNA Phosphodiesterase 1 Targeting for Modulation of Camptothecin-Based Treatment
Beretta, G. L., Cossa, G., Gatti, L., Zunino, F., & Perego, P. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790979971 · Cited by 50
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy
Akiyama, Y., Fujita, K., Nagashima, F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn645 · Cited by 46
Self-citationMiya, T., Goya, T., Fujii, H., et al. (2001) · Investigational New Drugs · doi:10.1023/a:1006456717846 · Cited by 45
Fujita, K., Nagashima, F., Yamamoto, W., Endo, H., Sunakawa, Y., Yamashita, K., Ishida, H., Mizuno, K., Matsunaga, M., Araki, K., et al. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2137 · Cited by 38
Self-citationKudoh, S., Fukuoka, M., Masuda, N., Yoshikawa, A., Kusunoki, Y., Matsui, K., Negoro, S., Takifuji, N., Nakagawa, K., Hirashima, T., et al. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03071.x · Cited by 38
Renal Function as a Predictor of Irinotecan-induced Neutropenia
de Jong, F., van der Bol, J. M., Mathijssen, R. H. J., van Gelder, T., Wiemer, E. A. C., Sparreboom, A., & Verweij, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100513 · Cited by 38
Schaaf, L. J., Hammond, L. A., Tipping, S. J., Goldberg, R. M., Goel, R., Kuhn, J. G., Miller, L. L., Compton, L. D., Cisar, L. A., Elfring, G. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2152 · Cited by 37
Sex-dependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBPα, and RXRα
Li, J., Wan, Y., Na, S., Liu, X., Dong, G., Yang, Z., Yang, J., & Yue, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.010 · Cited by 34
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients
Sai, K., Saito, Y., Fukushima‐Uesaka, H., Kurose, K., Kaniwa, N., Kamatani, N., Shirao, K., Yamamoto, N., Hamaguchi, T., Kunitoh, H., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0634-1 · Cited by 22
Han, J., Lee, G. K., Yoo, S. Y., Yoon, S. J., Cho, E. Y., Kim, H. T., & Lee, J. S. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.46 · Cited by 17
Irinotecan Pharmacogenetics: A Finished Puzzle?
Phelps, M. A., & Sparreboom, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3387 · Cited by 15
Irinotecan in the treatment of elderly patients with advanced colorectal cancer
Sastre, J., Puente, J., García-Sáenz, J. Á., & Díaz‐Rubio, E. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.05.008 · Cited by 9
Cited by
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 877
5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation
Cho, Y.-H., Ro, E. J., Yoon, J.-S., Mizutani, T., Kang, D.-W., Park, J.-C., Il Kim, T., Clevers, H., & Choi, K.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-19173-2 · Cited by 336
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Shaojun, C., Li, H., Haixin, H., & Guisheng, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1414754 · Cited by 54
Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
Metadata
- Authors
- Fujita, K.-I.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 21
- Issue
- 43
- Pages
- 12234
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2414279676
- Cited by
- 323
- References
- 104
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.